Cure
Recruiting now
Phase 1/2 • Sponsor: Fondazione Matilde Tettamanti Menotti De Marchi Onlus
A phase I/II trial tests donor-derived CARCIK CD123/33 cells in adults and children with relapsed or refractory AML and BPDCN before a stem cell transplant.
Read lead report →
Cure
Completed
Phase 1 • Sponsor: City of Hope Medical Center
A phase 1 trial tests engineered donor T cells plus interleukin-2 delivered into recurrent malignant glioma tumors to see if the approach is safe and feasible.
Read report →
Cure
Not yet recruiting
Phase 3 • Sponsor: AstraZeneca
A Phase 3 trial tests whether adding durvalumab to FLOT chemotherapy before and after surgery improves outcomes for people with resectable stomach and junction
Read report →
Cure
Completed
Phase 3 • Sponsor: Institut Paoli-Calmettes
A phase 3 trial compares two donor stem cell transplant strategies for older adults with blood cancers who lack a matched sibling donor.
Read report →
Cure
Recruiting now
Sponsor: Oslo University Hospital
A trial tests whether liver transplantation can extend survival and preserve quality of life in people with bile duct cancer that surgery cannot remove.
Read report →
Cure
Not yet recruiting
Sponsor: Tianjin Medical University General Hospital
Researchers test whether a personalized stem cell transplant can reset the immune system and stop multiple sclerosis from returning, letting patients live witho
Read report →
Cure
Recruiting now
Phase 1/2 • Sponsor: Tianjin Medical University General Hospital
A Phase 1/2 trial tests whether BAFF-R CAR-T cell therapy can reset the immune system in hard-to-treat neuroimmune diseases like CIDP, NMOSD, and myasthenia gra
Read report →
Cure
Not yet recruiting
Phase 2 • Sponsor: AbelZeta Inc.
A phase 2 trial tests a dual-target CAR-T therapy, prizloncabtagene autoleucel, in people with large B-cell lymphoma that returned after standard CAR-T treatmen
Read report →
Cure
Not yet recruiting
Phase 1/2 • Sponsor: Ausper Biopharma Co., Ltd.
A phase 1/2 trial tests AHB-137 followed by TVAX-008 in people with chronic hepatitis B, aiming for a functional cure after stopping standard antivirals.
Read report →
Cure
Not yet recruiting
Phase 1 • Sponsor: Peking University First Hospital
A phase 1 trial tests a single intravenous gene therapy, BBM-L101, in children with limb-girdle muscular dystrophy type 2D/R3 to assess safety and muscle protei
Read report →